Re­call re­port: Pfiz­er pulls even more Chan­tix lots as ni­trosamine con­t­a­m­i­na­tion wor­ries grow

It’s been a month since Pfiz­er was forced to re­call bot­tles of its an­ti-smok­ing drug Chan­tix, but the counter was set back to ze­ro last week as the com­pa­ny re­called all of its lots of 0.5 mg and 1 mg tablets due to in­creased lev­els of ni­trosamines.

Dis­tri­b­u­tion of Chan­tix was stopped in June, and the com­pa­ny re­called four lots of the drug af­ter find­ing el­e­vat­ed lev­els of can­cer-caus­ing ni­trosamines. Then, in Ju­ly, the FDA said it would still al­low cer­tain man­u­fac­tur­ers to dis­trib­ute batch­es of the drug that have more than the usu­al ni­trosamine lev­els, so long as it re­mains un­der the in­ter­im ac­cept­able lim­it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.